The word is missing. Not the one you’re vaguely searching for, but the one you’ve always known. Something familiar suddenly feels foreign for a moment. The familiar face carries a name that refuses to come.
These memory lapses, taken in isolation, resemble fatigue or distraction. But they are sometimes the first symptoms of a process that develops silently.
When they multiply and take hold, they paint a picture that medicine has long approached in fragments, without connecting the threads. Something is going wrong, gradually, silently. The brain is not just losing memories: it is defending itself against a threat it can no longer contain.
Alzheimer’s disease tells a precise biological story, that of an organism mobilizing its defenses to the point of exhaustion, whose protective mechanisms ultimately make its inner terrain more rigid.
Amyloid-beta: an antimicrobial defense that becomes toxic
For more than twenty years, the dominant hypothesis in Alzheimer’s research rested on a simple premise: the amyloid plaques observed in patients’ brains were the direct cause of the disease. All that was needed was to eliminate them to stop or slow progression. Dozens of drugs were developed on this basis. Almost all of them failed.
The plaques sometimes disappeared, but patients continued to decline. This observation forced the research community to look elsewhere. The hypothesis emerging today overturns the conventional interpretation.
Amyloid-beta, this protein long considered a simple toxic waste product, possesses real antimicrobial properties. It traps and neutralizes bacteria and viruses. The brain may produce it in defense against a chronic infection that never goes away.
A useful defense at first, which becomes toxic when mobilized relentlessly. An exhausted sentinel that no longer knows how to lower its shield.
The work of Moir and Tanzi at Harvard showed that amyloid-beta behaves like a natural antimicrobial peptide. It aggregates around pathogens to prevent them from spreading. The problem arises when this response becomes chronic.
The brain remains in a permanent state of alert, produces amyloid continuously, and the aggregates accumulate until they disrupt neuronal connections. The defense turns against the terrain it was supposed to protect.
Periodontal disease and the brain: a documented association
One of the most troubling discoveries of recent years concerns Porphyromonas gingivalis, the bacterium responsible for chronic periodontal disease. Researchers have found its toxic enzymes, gingipains, in the brains of Alzheimer’s patients. These enzymes are present in living brain tissue, and their concentration correlates with the severity of the disease.
This bacterium does not remain confined to the mouth. It can migrate through the bloodstream or cranial nerves, cross the weakened blood-brain barrier, and establish itself in the brain. Once there, it triggers a chronic immune response.
The brain produces amyloid-beta to try to contain it, but the infection persists, and amyloid production never stops. A temporary defense becomes a permanent state.
Studies show that people with a history of severe periodontal disease (periodontitis, chronic gingival inflammation) have an increased risk of developing Alzheimer’s. The state of the mouth, the quality of the gingival barrier, and the chronic infectious load play a role in the brain’s vulnerability. Oral health can directly influence the systemic inflammatory terrain and, by extension, the protection of the nervous system.
Fibrin: when blood invades the brain
The blood-brain barrier is an essential biological frontier. It filters what enters the brain and maintains a stable environment for neurons. But this barrier can become permeable, particularly under the influence of chronic inflammation, insulin resistance, or prolonged metabolic stress.
When it gives way, blood proteins that have no business being in the brain begin to enter it. Among them, fibrinogen.
Fibrinogen is a coagulation protein. In the blood, it transforms into fibrin to form clots and stop bleeding. In the brain, it has no such function.
It aggregates into structures resistant to degradation, activates the brain’s immune cells, the microglia, and triggers local inflammation that destroys synaptic connections. The work of Katerina Akassoglou at the Gladstone Institute showed that cerebral fibrin can damage neurons independently of amyloid. It acts alone, or in synergy with amyloid plaques, to amplify neurodegeneration.
Fibrin actively participates in the destruction of nerve tissue. Antibodies capable of targeting and neutralizing cerebral fibrin are currently in clinical development. The idea is to block this inflammatory cascade at its source, without touching normal blood coagulation. This work opens a new therapeutic avenue, one that does not rely on eliminating amyloid.
Brain insulin resistance: a weakened metabolic terrain
The brain is an energy-hungry organ. It consumes about 20% of the body’s total energy, while representing only 2% of its mass. This energy comes from glucose or ketone bodies.
But where does this disruption of carbohydrate metabolism come from? The human body is not designed to receive glucose in a continuous flow. For hundreds of thousands of years, our metabolism was built on a diet low in carbohydrates, with periods of natural fasting.
Today, we eat bread at breakfast, pasta for lunch, rice in the evening, fruit as a snack, juice in the afternoon. This total carbohydrate load, whether it comes from whole wheat bread, potatoes, legumes, or processed foods, constantly demands insulin.
This repeated signal, day after day, eventually wears out the receptors. Cells stop responding properly to insulin. This is what we call insulin resistance.
And the brain is not spared. When carbohydrate metabolism goes awry, the brain pays the price.
When neurons become insulin resistant, they take up glucose less effectively. They lack energy, even when blood sugar levels are high. This chronic energy deprivation weakens synaptic connections, accelerates cell death, and promotes the accumulation of abnormal proteins. Some researchers speak of Alzheimer’s as “type 3 diabetes,” a mechanistic description of the metabolic terrain underlying the disease.
Ketone bodies offer an alternative energy pathway. They are produced by the liver from fats, particularly in the context of carbohydrate restriction or prolonged fasting. Unlike glucose, ketone bodies do not depend on insulin to enter cells. They cross the blood-brain barrier easily and provide stable energy to the brain.
Studies show that a ketogenic diet can improve cognitive function in some patients in the early stages of Alzheimer’s. A metabolic lever that supports the brain when the glucose pathway is failing.
Nattokinase and serrapeptase: enzymes that degrade fibrils
Nattokinase is an enzyme extracted from natto, a fermented Japanese soy food. It is known for its ability to degrade blood fibrin, but its action does not stop there. Research shows it can also break down amyloid fibrils Aβ42 and Aβ40, the most toxic forms of amyloid-beta. It acts directly on protein aggregates, fragments them, and facilitates their clearance by glial cells.
Studies in mouse models have documented a protective effect of nattokinase on the integrity of the blood-brain barrier. It reduces permeability, limits the entry of blood proteins into the brain, and decreases local inflammation. A biological tool that acts on two fronts: fibrin and amyloid.
Serrapeptase, another enzyme of bacterial origin, shares similar properties. It degrades abnormal proteins, reduces inflammation, and improves microcirculation.
These enzymes are not drugs. They are not governed by the same clinical protocols. But they fit into a biologically coherent rationale: supporting the body’s natural protein degradation mechanisms, reducing the inflammatory load, and restoring fluidity to the inner terrain. They do not replace comprehensive care, but they can be part of a broader approach.
What research connects and what it doesn’t prove yet
Current Alzheimer’s research documents strong associations between systemic inflammation, blood-brain barrier permeability, chronic infections, insulin resistance, and the accumulation of abnormal proteins. These mechanisms are not isolated. They reinforce each other.
A weakened barrier lets blood proteins in that activate inflammation. Chronic inflammation worsens insulin resistance. Insulin resistance deprives the brain of energy.
Lack of energy weakens neurons and promotes amyloid aggregation. Amyloid, produced in defense, eventually becomes toxic. The circle closes.
What science cannot yet state with certainty is the exact causal sequence. Which mechanism triggers the others? Is it the chronic infection that initiates everything?
Is it insulin resistance that first weakens the terrain? Is it barrier permeability that opens the door to the other dysfunctions? Current data do not allow us to decide. What is clear is that these mechanisms converge, and that their accumulation over time builds the terrain of the disease.
Interventions targeting a single mechanism have often failed because they did not account for this complexity. Eliminating amyloid without correcting inflammation, barrier permeability, or insulin resistance is not enough. The terrain remains fragile.
The disease progresses. This systemic reading was missing, and it is beginning to emerge in the most recent work.
Taking back control of the biological terrain
Research documents levers, but you decide which ones to explore, in what order, and with what intensity. The biological terrain is not fixed.
It responds to the signals we send it, day after day, meal after meal, night after night. Sleep quality directly influences the clearance of brain waste via the glymphatic system, that drainage network that activates mainly during deep slow-wave sleep. The glymphatic system flushes out abnormal proteins and toxins accumulated during the day.
When this deep sleep is fragmented or insufficient, the continuity of nighttime clearance is disrupted and the brain clears less effectively what it accumulates.
Oral health deserves real attention. Periodontitis, chronic gingival inflammation, and bleeding when brushing are not minor details. They are entry points for bacteria that can migrate to the brain. Taking care of your teeth, seeing the dentist regularly, and maintaining rigorous oral hygiene are part of neurological prevention.
The total chronic carbohydrate load, whether from bread, pasta, rice, fruit, or processed foods, builds a terrain of insulin resistance that weakens the brain. Reducing this load, stabilizing blood sugar, favoring quality fats and well-tolerated proteins are documented metabolic levers. They do not cure Alzheimer’s, but they support the brain’s energy terrain.
Enzymes such as nattokinase and serrapeptase fit into a comprehensive approach aimed at reducing the inflammatory load, improving circulation, and supporting the natural mechanisms for degrading abnormal proteins. They replace nothing. They complement.
Alzheimer’s disease is not an inevitable genetic fate. It results from a biological terrain that has gradually deteriorated, under the effect of multiple cumulative factors. Taking back control of this terrain takes time, consistency, and a lucid reading of what the body is trying to say. The levers exist, and they are documented.
Frequently Asked Questions
How can you tell an ordinary lapse from an early sign of Alzheimer's disease?
An occasional lapse linked to fatigue or mental load remains isolated and does not disrupt daily life. The signals that deserve attention multiply and take hold: repeated difficulty finding common words, disorientation in familiar places, forgetfulness that affects daily life (missed appointments, misplaced objects with no memory of moving them). If these signals persist or worsen, consulting a neurologist or geriatrician allows the situation to be assessed.
How is Alzheimer's disease diagnosed early?
Diagnosis relies on a comprehensive medical assessment conducted by a neurologist or geriatrician: cognitive tests (memory, language, orientation), brain imaging (MRI or CT scan) to observe atrophy in certain areas, and sometimes measurement of biomarkers in cerebrospinal fluid or by PET scan (amyloid-beta and tau proteins). No self-diagnosis is possible: only a professional can make the diagnosis and rule out other reversible causes (B12 deficiency, hypothyroidism, depression).
What causes Alzheimer's disease?
The disease results from a convergence of mechanisms that develop over time: accumulation of amyloid-beta protein (the brain's defense response to aggression), fibrin deposits that weaken the blood-brain barrier, brain insulin resistance that deprives neurons of energy, dysfunction of the glymphatic system (the brain's nighttime drainage), and chronic infections that sustain inflammation. It is never a single isolated factor, but a terrain that gradually deteriorates.
Why is Alzheimer's disease sometimes called type 3 diabetes?
Some researchers use this term to describe the insulin resistance observed in the brains of Alzheimer's patients: neurons no longer take up glucose properly, their usual fuel, which weakens their function and survival. This mechanistic avenue sheds light on one aspect of the disease, but does not fully define it: Alzheimer's remains a multi-mechanism pathology where insulin plays a role among others.
Ketogenic diet and Alzheimer's: what does research actually say?
Preliminary studies observe that a ketogenic diet, by producing ketone bodies usable by the brain as an alternative fuel to glucose, could improve certain cognitive functions in patients at an early stage. These data still need to be confirmed by larger trials: keto is not an established treatment, but a metabolic support avenue explored in some research protocols. It never replaces medical follow-up.
Nattokinase and serrapeptase in Alzheimer's: research avenue or treatment?
Nattokinase and serrapeptase are enzymes studied for their ability to degrade fibrin and certain protein aggregates, which could support cerebral circulation and the drainage of metabolic waste. These avenues remain experimental: they are neither a medication nor a validated treatment for Alzheimer's, and in no way replace neurological follow-up. They fit into a terrain-support approach, documented but not established.
DISCLAIMER: This article is for informational purposes only and does not replace personalized medical advice. The information presented aims to clarify documented biological mechanisms; any decision about your health, especially with medical conditions, ongoing treatment, or scheduled surgery, should be discussed with a qualified healthcare professional.
Sources and References
-
Steen E et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes? — Type 3 diabetes / brain insulin signaling
-
Soscia SJ et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. — Antimicrobial hypothesis of amyloid-beta
-
Kumar DK et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. — In vivo validation of amyloid antimicrobial defense
-
Dominy SS et al. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. — P. gingivalis / gingipains in Alzheimer's brains
-
Merlini M et al. Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer's Disease Model. — Fibrinogen / microglia / synapses
-
Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics. — Fibrin / blood-brain barrier / neurological diseases review
-
Nicoloso Simoes-Pires E et al. Synergistic effects of the Abeta/fibrinogen complex on synaptotoxicity, neuroinflammation, and blood-brain barrier damage in Alzheimer's disease models. — Aβ/fibrinogen synergy (Alzheimer's & Dementia 2025; Strickland lab)
-
Hsu RL et al. Amyloid-degrading ability of nattokinase from Bacillus subtilis natto. — Nattokinase and amyloid fibril degradation
-
Nattokinase as a potential therapeutic agent for preventing blood-brain barrier dysfunction in neurodegenerative disorders. — Nattokinase and blood-brain barrier integrity